Drug Insight: Gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy

Yohann Loriot, Gabriel Perlemuter, David Malka, Frédérique Penault-Lorca, Valérie Boige, Eric Deutsch, Christophe Massard, Jean Pierre Armand, Jean Charles Soria

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations

Abstract

Recent advances in the understanding of molecular mechanisms of cancer have led to the development of novel compounds that target specific cancer pathways. These drugs encompass monoclonal antibodies and tyrosine and non-tyrosine kinase inhibitors, and have been approved by the FDA and the European Medicines Agency, among others, for cancer treatment. These agents are associated with several toxic effects including potentially unacceptable gastrointestinal adverse effects. Diarrhea and hepatotoxicity, the most common adverse events experienced with these treatments, can frequently lead to treatment discontinuation and consequently decreased cancer control. We review the incidence and clinical patterns of the gastrointestinal and hepatic toxic effects induced by the main molecular-targeted therapies and propose some hypotheses for the causes of each adverse event.

Original languageEnglish
Pages (from-to)268-278
Number of pages11
JournalNature Clinical Practice Oncology
Volume5
Issue number5
DOIs
StatePublished - May 2008
Externally publishedYes

Fingerprint

Dive into the research topics of 'Drug Insight: Gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy'. Together they form a unique fingerprint.

Cite this